U.S. Physical Therapy, Inc. (NYSE:USPH) – Research analysts at Cantor Fitzgerald issued their FY2018 EPS estimates for shares of U.S. Physical Therapy in a research report issued to clients and investors on Sunday. Cantor Fitzgerald analyst J. France forecasts that the company will post earnings per share of $2.50 for the year. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price target on the stock.
U.S. Physical Therapy (NYSE:USPH) last posted its earnings results on Thursday, March 8th. The company reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. The business had revenue of $109.20 million for the quarter, compared to the consensus estimate of $104.12 million. U.S. Physical Therapy had a net margin of 5.38% and a return on equity of 13.12%.
U.S. Physical Therapy (NYSE:USPH) opened at $83.25 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 2.04 and a debt-to-equity ratio of 0.28. The company has a market cap of $1,075.69, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.13 and a beta of 1.16. U.S. Physical Therapy has a 12-month low of $56.50 and a 12-month high of $87.50.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Wednesday, March 21st will be given a $0.23 dividend. The ex-dividend date of this dividend is Tuesday, March 20th. This represents a $0.92 dividend on an annualized basis and a dividend yield of 1.11%. This is an increase from U.S. Physical Therapy’s previous quarterly dividend of $0.20. U.S. Physical Therapy’s payout ratio is presently 45.71%.
In other news, Director Mark J. Brookner sold 2,625 shares of U.S. Physical Therapy stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $71.23, for a total value of $186,978.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Lawrance W. Mcafee sold 5,000 shares of U.S. Physical Therapy stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $83.35, for a total transaction of $416,750.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,625 shares of company stock worth $1,295,029. Insiders own 3.10% of the company’s stock.
Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in U.S. Physical Therapy during the 3rd quarter worth approximately $170,000. UBS Asset Management Americas Inc. purchased a new stake in U.S. Physical Therapy during the 4th quarter worth approximately $206,000. Envestnet Asset Management Inc. grew its position in U.S. Physical Therapy by 48.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 3,704 shares of the company’s stock worth $267,000 after purchasing an additional 1,212 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in U.S. Physical Therapy by 59.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,770 shares of the company’s stock worth $231,000 after purchasing an additional 1,412 shares during the last quarter. Finally, Trustcore Financial Services LLC purchased a new stake in U.S. Physical Therapy during the 4th quarter worth approximately $296,000. 96.53% of the stock is currently owned by hedge funds and other institutional investors.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.